PMID- 31866476
OWN - NLM
STAT- MEDLINE
DCOM- 20220429
LR  - 20220429
IS  - 1096-3650 (Electronic)
IS  - 1044-579X (Linking)
VI  - 80
DP  - 2022 May
TI  - Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel 
      therapeutic strategy.
PG  - 1-17
LID - S1044-579X(19)30405-5 [pii]
LID - 10.1016/j.semcancer.2019.12.008 [doi]
AB  - The phosphatidylinositol 3-kinase (PI3K)-Akt and the mammalian target of 
      rapamycin (mTOR) represent two vital intracellular signaling pathways, which are 
      associated with various aspects of cellular functions. These functions play vital 
      roles in quiescence, survival, and growth in normal physiological circumstances 
      as well as in various pathological disorders, including cancer. These two 
      pathways are so intimately connected to each other that in some instances these 
      are considered as one unique pathway crucial for cell cycle regulation. The 
      purpose of this review is to emphasize the role of PI3K-Akt-mTOR signaling 
      pathway in different cancer conditions and the importance of natural products 
      targeting the PI3K-Akt-mTOR signaling pathway. This review also aims to draw the 
      attention of scientists and researchers to the assorted beneficial effects of the 
      numerous classes of natural products for the development of new and safe drugs 
      for possible cancer therapy. We also summarize and critically analyze various 
      preclinical and clinical studies on bioactive compounds and constituents, which 
      are derived from natural products, to target the PI3K-Akt-mTOR signaling pathway 
      for cancer prevention and intervention.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Tewari, Devesh
AU  - Tewari D
AD  - Department of Pharmacognosy, School of Pharmaceutical Sciences, Lovely 
      Professional University, Phagwara 144 411, Punjab, India. Electronic address: 
      devesh.24531@lpu.co.in.
FAU - Patni, Pooja
AU  - Patni P
AD  - Sharda School of Pharmacy, Gujarat Technical University, Gandhinagar 382 610, 
      Gujarat, India.
FAU - Bishayee, Anusha
AU  - Bishayee A
AD  - Pine View School, Osprey, FL 34229, USA.
FAU - Sah, Archana N
AU  - Sah AN
AD  - Department of Pharmaceutical Sciences, Faculty of Technology, Bhimtal Campus, 
      Kumaun University, Nainital 263 136, Uttarakhand, India.
FAU - Bishayee, Anupam
AU  - Bishayee A
AD  - Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA. Electronic 
      address: abishayee@lecom.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191219
PL  - England
TA  - Semin Cancer Biol
JT  - Seminars in cancer biology
JID - 9010218
RN  - 0 (Biological Products)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - *Biological Products/pharmacology/therapeutic use
MH  - Humans
MH  - *Neoplasms/drug therapy
MH  - Phosphatidylinositol 3-Kinase/metabolism/pharmacology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors/therapeutic use
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - Breast cancer
OT  - Lymphoma
OT  - Natural compounds
OT  - PI3K-Akt
OT  - Phytochemicals
OT  - Polyphenols
OT  - Prostate cancer
OT  - Sarcoma
OT  - mTOR
EDAT- 2019/12/24 06:00
MHDA- 2022/04/30 06:00
CRDT- 2019/12/24 06:00
PHST- 2019/09/17 00:00 [received]
PHST- 2019/12/01 00:00 [revised]
PHST- 2019/12/03 00:00 [accepted]
PHST- 2019/12/24 06:00 [pubmed]
PHST- 2022/04/30 06:00 [medline]
PHST- 2019/12/24 06:00 [entrez]
AID - S1044-579X(19)30405-5 [pii]
AID - 10.1016/j.semcancer.2019.12.008 [doi]
PST - ppublish
SO  - Semin Cancer Biol. 2022 May;80:1-17. doi: 10.1016/j.semcancer.2019.12.008. Epub 
      2019 Dec 19.